Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
LOPURIN is an oral tablet small-molecule product approved by Abbott in 1980 for an undisclosed indication. The specific mechanism of action and therapeutic target are not publicly detailed in the available data.
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a smaller, transitional brand team focused on market defense and transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
Worked on LOPURIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOPURIN currently shows zero linked job openings, reflecting its mature lifecycle stage and approaching loss of exclusivity. Career opportunities on this product are limited and focused on market maintenance and competitive defense rather than growth or innovation.